Results 1 to 10 of about 2,403,288 (173)

Bilineage T-lymphoblastic/myeloid extramedullary blast crisis in chronic myelogenous leukemia

open access: yesIndian Journal of Pathology and Microbiology, 2016
The blast crisis of chronic myelogenous leukemia (CML) can be hematological or extramedullary. About 25% of these cases fulfill the criteria for mixed phenotype acute leukemia.
Indu M Nair, M Feroze, K P Aravindan
doaj   +2 more sources

Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia - accelerated phase: A rare case with review of the literature

open access: yesIndian Journal of Pathology and Microbiology, 2013
Chronic myelogenous leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different and common hematological neoplasms. Their coexistence is rare, especially CLL developing in a patient of CML. Till date, only a few cases are reported and all had
Narender Kumar   +3 more
doaj   +2 more sources

The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia

open access: yesOncology Reviews, 2011
Imatinib mesylate, a small-molecule inhibitor of BCRABL tyrosine kinase activity, has emerged as the well-recognized standard of treatment for chronic myelogenous leukemia (CML). Indeed, both its efficacy, tolerability, as well as cost-effectiveness have
Camillo Porta, Federica Tagliani
doaj   +2 more sources

Protocol for isolation and analysis of the leukemia stem cells in BCR-ABL-driven chronic myelogenous leukemia mice [PDF]

open access: yesSTAR Protocols, 2023
Summary: Practical procedures for sorting and analysis of leukemia stem cells (LSCs) are to improve our understanding of chronic myelogenous leukemia (CML).
Chang Liu   +3 more
doaj   +2 more sources

Granulocytic Sarcoma with Compressive Myelopathy: A Rare Presentation of Chronic Myelogenous Leukemia [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2014
Granulocytic sarcoma occurs most commonly in acute myelogenous leukemia. The appearance of granulocytic sarcoma in chronic myelogenous leukemia signals accelerated phase/ blast transformation.
Abhijeet P. Ganapule   +4 more
doaj   +1 more source

Acute appendicitis revealing a diagnosis of chronic myelogenous leukemia

open access: yesClinical Case Reports, 2021
Gastrointestinal manifestations of leukemias have been well recognized. Typically, acute leukemias cause typhlitis or appendicitis more commonly than chronic leukemias.
Rita Ahmad   +6 more
doaj   +1 more source

A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib

open access: yesClinical Case Reports, 2022
Patients with chronic myelogenous leukemia (CML) harboring the T315I mutation who progress to blast phase CML while on ponatinib may be successfully treated with asciminib monotherapy following induction therapy with cytotoxic chemotherapy.
Sarah Tomassetti, Jennifer Lee, Xin Qing
doaj   +1 more source

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

open access: yesHaematologica, 2013
Second generation tyrosine kinase inhibitors have recently been introduced as first-line treatment for chronic phase chronic myelogenous leukemia. We aimed to evaluate the efficacy and safety of 2nd generation tyrosine kinase inhibitors versus imatinib ...
Ronit Gurion   +9 more
doaj   +1 more source

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy

open access: yesCase Reports in Cardiology, 2018
Decitabine is a pyrimidine analogue of nucleoside cytidine, used for the treatment of myelodysplastic syndromes, chronic myelogenous leukemia, and acute myelogenous leukemia.
Pradyumna Agasthi   +4 more
doaj   +1 more source

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia

open access: yesClinical Case Reports, 2017
Key Clinical Message The availability of kinase and other small‐molecule inhibitors to treat hematologic malignancies is increasing. Accordingly, novel regimens that employ these therapeutics are rapidly evolving.
Lauren K. Shea   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy